Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STM 434 alone and in combination with liposomal doxorubicin in advanced solid tumors
NCT02262455Phase 1Completed
- Sponsor
- Santa Maria Biotherapeutics, Inc.
- Start
- Oct 2014
- Primary completion
- Jan 2017
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label trial of STM434 in ovarian cancer, fallopian tube cancer (PFTC), endometrial cancer (EC) and 1 more (2 arms), sponsored by Santa Maria Biotherapeutics, Inc. Primary endpoint: Maximum Tolerated Dose at 28 days. Started Oct 2014; status: completed.
02
Drugs
STM434
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)endometrial cancer (EC)solid tumor
Beyond the preview
Go deeper on NCT02262455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02262455.